Acupuncture (Jin’s Three-Needle) versus sham acupuncture in treating mild-to-moderate depression: Study protocol for randomized clinical trial

0Citations
Citations of this article
2Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background Mild-to-moderate depression is an increasing public health problem worldwide, which is more prevalent than major depression but has received less attention Currently, no existing highly effective pharmacological treatments with minimal adverse reactions are available for this condition. Jin’s Three-Needle Acupuncture (JTN) may be an alternative treatment option for mild-to-moderate depression patients. Methods This is a prospective, parallel-arm, single-blind, randomized controlled trial. We plan to enroll 106 participants with mild-to-moderate depression, randomly assigning them to receive either JTN or sham acupuncture (SA) in a 1:1 ratio. All participants will receive the JTN treatment or SA treatment for 8 weeks (3 per week). The primary outcome will be assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17). Secondary outcomes will include the Self-Rating Depression Scale (SDS), Pittsburgh Sleep Quality Index (PSQI), Hamilton Anxiety Scale (HAMA), Self-Rating Anxiety Scale (SAS), and the Traditional Chinese Medicine Syndrome Score Scale (TCMSS). Evaluations will be performed at baseline and at weeks 4, 6, and 8 after treatment initiation. Statistical analyses will be conducted on both the intention-to-treat (ITT) and per-protocol (PP) datasets. Discussion This study aims to provide high-quality evidence regarding the efficacy and safety of JTN as a treatment for mild-to-moderate depression. Additionally, the mechanisms underlying the effects of JTN in treating mild-to-moderate depression will be explored.

Cite

CITATION STYLE

APA

Wen, H., Wang, J., Zhang, K., Zhang, N., Shan, Y., Yang, X., … Zhang, C. (2025). Acupuncture (Jin’s Three-Needle) versus sham acupuncture in treating mild-to-moderate depression: Study protocol for randomized clinical trial. PLOS ONE, 20(12 December). https://doi.org/10.1371/journal.pone.0338341

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free